Technologies
Rithim Biologics® is developing technologies utilizing gene therapy for reduction; prevention; and/or treatment of tachycardias (fast heart rates). Our current focus is on:
- Development of KCNH2-G628S gene therapy for post-operative atrial fibrillation (POAF) in patients undergoing cardiac bypass (CABG) and heart valve surgeries.
- Development of proprietary instrumentations to facilitate efficacious delivery of a range of gene therapies for the treatment of cardiac tachyarrhythmias.
PreClinical Example of Heart Painting
![1 1](https://rithimbiologics.com/wp-content/uploads/2020/12/Webp.net-resizeimage-4.png)
SafeBrush™
Patent Pending
![3 3](https://rithimbiologics.com/wp-content/uploads/2020/12/Webp.net-resizeimage-5.png)
TheraKit™ with AdKCNH2-G628S gene therapy with SafeBrush™ for open chest or the DAAViS™ catheter system for less invasive procedures
![2 2](https://rithimbiologics.com/wp-content/uploads/2020/12/Webp.net-resizeimage-3.png)
DAAViS™
US Patent 11,369,773 B2
![Webp.net-resizeimage (6) Webp.net-resizeimage (6)](https://rithimbiologics.com/wp-content/uploads/2020/12/Webp.net-resizeimage-6.png)